CJC-1295 research guide for Eifuku. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 isn't found on pharmacy shelves in Eifuku or virtually any local market — this is a specialist compound distributed through a dedicated online market. The practical takeaway for Eifuku researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. This guide takes Eifuku researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Eifuku studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade CJC-1295
The first step for any Eifuku researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — organic rankings are no guide to actual CJC-1295 quality. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger severe inflammatory responses even at minute levels. Negative indicators in CJC-1295 vendor evaluation: prices far under typical market pricing, vague sourcing information, no community presence, and COAs that do not include endotoxin results. For Eifuku researchers making a first CJC-1295 purchase: apply these quality criteria before ordering, begin with a small order, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Eifuku
COA-verified · International tracking · Research grade
CJC-1295 operates outside the framework of pharmaceutical oversight — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no discount compensates for this missing data. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not approved for human use and its known risks are not comparable to approved pharmaceuticals.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
